First Wave BioPharma Files 8-K

TL;DR

FWBI filed an 8-K on 3/18, standard reporting.

AI Summary

First Wave BioPharma, Inc. filed an 8-K on March 18, 2024, reporting other events and financial statements. The company, formerly AzurRx BioPharma, Inc., is incorporated in Delaware and headquartered in Boca Raton, Florida.

Why It Matters

This filing indicates ongoing corporate activity and reporting requirements for First Wave BioPharma, Inc., providing transparency to investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for reporting events and financial statements, not indicating any immediate significant operational or financial changes.

Key Players & Entities

• First Wave BioPharma, Inc. (company) — Registrant
• AzurRx BioPharma, Inc. (company) — Former Company Name
• March 18, 2024 (date) — Date of Report
• Boca Raton, Florida (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share FWBI Nasdaq Capital Marke

Filing Documents

• tm249108d1_8k.htm (8-K) — 32KB
• tm249108d1_ex99-1.htm (EX-99.1) — 17KB
• 0001104659-24-035598.txt ( ) — 225KB
• fwbi-20240318.xsd (EX-101.SCH) — 3KB
• fwbi-20240318_lab.xml (EX-101.LAB) — 33KB
• fwbi-20240318_pre.xml (EX-101.PRE) — 22KB
• tm249108d1_8k_htm.xml (XML) — 4KB

01

Item 8.01 Entry into a Material Definitive Agreement. On March 18, 2024, the First Wave BioPharma, Inc. (the "Company") issued a press release announcing that two abstracts have been accepted for presentation at the 2024 Digestive Disease Week Conference taking place from May 18-21, 2024, in Washington, D.C. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits.

Forward Looking Statements

Forward Looking Statements Any statements in this Current Report about the future expectations, plans and prospects of the Company, including without limitation, statements regarding: the Company's acquisition of ImmunogenX, Inc., a Delaware Corporation ("ImmunogenX") (the acquisition of ImmunogenX by the Company, the "Merger"), stockholder approval of the conversion of the Series G Preferred Stock, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "hypothesize," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to those set forth under the caption "Risk Factors" in this Current Report on Form 8-K and in the Company's most recent Annual Report on Form 10-K filed with the SEC, as supplemented by its subsequent Quarterly Reports on Form 10-Q and in other filings that makes with the SEC. In addition, any forward-looking statements included in this Current Report represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any intention to update any forward-looking statements included in this Current Report. No Offer or Solicitation; Important Information About the Merger and Where to Find It This Current Report on Form 8-K is not a proxy constitute an offer to sell or a solicitation of an offer to buy the securities of the Company or ImmunogenX, nor shall there be any sale of any such securities in any state or jurisdiction i

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. First Wave BioPharma, Inc. March 18, 2024 By: /s/ James Sapirstein Name: James Sapirstein Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR